| MIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy. | MIR27A Gene Polymorphism Modifies the Effect of Common DPYD Gene Variants on Severe Toxicity in Patients with Gastrointestinal Tumors Treated with Fluoropyrimidine-Based Anticancer Therapy.
Ikonnikova A, Fedorinov D, Gryadunov D, Heydarov R, Lyadova M, Moskalenko A, Mikhailovich V, Emelyanova M, Lyadov V., Free PMC Article | 09/19/2024 |
| DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review. | DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review.
Chan TH, Zhang JE, Pirmohamed M., Free PMC Article | 09/11/2024 |
| Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants. | Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants.
van Kuilenburg ABP, Pleunis-van Empel MCH, Brouwer RB, Sijben AEJ, Knapen DG, Oude Munnink TH, van Zanden JJ, Janssens-Puister J, Dobritzsch D, Meinsma R, Meijer-Jansen J, van Dooren SJM, Vijzelaar R, Pop A, Salomons GS, Maring JG, Niezen-Koning KE. | 05/28/2024 |
| Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD). | Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD).
Zhang T, Ambrodji A, Huang H, Bouchonville KJ, Etheridge AS, Schmidt RE, Bembenek BM, Temesgen ZB, Wang Z, Innocenti F, Stroka D, Diasio RB, Largiadèr CR, Offer SM., Free PMC Article | 05/10/2024 |
| Common dihydropyrimidinase (DPYS) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort. | Common dihydropyrimidinase ( DPYS ) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort.
Medwid SJ, Mailloux JL, Wigle TJ, Kim RB. | 02/29/2024 |
| MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations. | MIR27A rs895819 TC genotype increases risk of fluoropyrimidine-induced severe toxicity independently of DPYD variations.
Ragia G, Biziota E, Koukaki T, Amarantidis K, Manolopoulos VG. | 02/21/2024 |
| Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity. | Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity.
Larrue R, Fellah S, Hennart B, Sabaouni N, Boukrout N, Van der Hauwaert C, Delage C, Cheok M, Perrais M, Cauffiez C, Allorge D, Pottier N., Free PMC Article | 02/6/2024 |
| Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction. | Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction.
Medwid S, Wigle TJ, Ross C, Kim RB., Free PMC Article | 09/16/2023 |
| Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study. | Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study.
Miarons M, Manzaneque Gordón A, Riera P, Gutiérrez Nicolás F, RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH)., Free PMC Article | 08/25/2023 |
| DPYD and TYMS polymorphisms as predictors of 5 fluorouracil toxicity in colorectal cancer patients. | DPYD and TYMS polymorphisms as predictors of 5 fluorouracil toxicity in colorectal cancer patients.
Khalij Y, Belaid I, Chouchane S, Amor D, Omezzine A, Ben Rejeb N, Ben Ahmed S, Bouslama A. | 08/2/2023 |
| Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping. | Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
Royer B, Launay M, Ciccolini J, Derain L, Parant F, Thomas F, Guitton J., Free PMC Article | 07/7/2023 |
| Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population. | Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A, Yoshino T, Saji S, Matsuda F., Free PMC Article | 05/4/2023 |
| Dihydropyrimidine dehydrogenase phenotype in peripheral blood mononuclear cells is related to adverse events of fluoropyrimidine-therapy. | Dihydropyrimidine dehydrogenase phenotype in peripheral blood mononuclear cells is related to adverse events of fluoropyrimidine-therapy.
Doornhof KR, van der Linden PD, Boeke GM, Willemsen AECAB, Daskapan A. | 03/29/2023 |
| Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between DPYD-genotype variants and P-uracil concentrations. | Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between DPYD-genotype variants and P-uracil concentrations.
Paulsen NH, Qvortrup C, Vojdeman FJ, Plomgaard P, Andersen SE, Ramlov A, Bertelsen B, Rossing M, Nielsen CG, Hoffmann-Lücke E, Greibe E, Spangsberg Holm H, Nielsen HH, Lolas IBY, Madsen JS, Bergmann ML, Mørk M, Fruekilde PBN, Bøttger P, Petersen PC, Nissen PH, Feddersen S, Bergmann TK, Pfeiffer P, Damkier P. | 03/3/2023 |
| DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation. | DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation.
Wigle TJ, Medwid S, Ross C, Schwarz UI, Kim RB., Free PMC Article | 02/4/2023 |
| Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype. | Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.
Medwid S, Wigle TJ, Kim RB. | 01/14/2023 |
| Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer. | Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer.
Almashagbah NA, Mahasneh AA, Bodoor KG., Free PMC Article | 10/15/2022 |
| Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer. | Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer.
Cevik M, Namal E, Sener ND, Koksal UI, Cagatay P, Deliorman G, Ciftci C, Karaalp A, Susleyici B. | 10/1/2022 |
| DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events. | DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.
de With M, Brufau G, van den Berg LA, de Man FM, Trajkovic M, Thijs MF, Castel R, Vermeer HJ, El Bouazzaoui S, van Hemel A, Matic M, Mathijssen RHJ, Bins S, van Schaik RHN. | 07/30/2022 |
| Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin. | Genetic influence of DPYD*9A polymorphism on plasma levels of 5-fluorouracil and subsequent toxicity after oral administration of capecitabine in colorectal cancer patients of South Indian origin.
Varma A, Jayanthi M, Dubashi B, Shewade DG, Sundaram R. | 06/18/2022 |
| Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients.", trans "Frecuencia y relevancia clinica de las variantes del gen DPYD en pacientes con tumores digestivos. | Frequency and clinical relevance of DPYD genetic variants in gastrointestinal cancer patients.
Riera P, Riba M, Bernal S, Virgili AC, Páez D, Moreno ME. | 04/9/2022 |
| Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer. | Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer.
Watanabe M, Katsumata K, Sumi T, Ishizaki T, Enomoto M, Shigoka M, Wada T, Kuwabara H, Mazaki J, Kasahara K, Tago T, Udo R, Nagakawa Y, Kawachi S, Tsuchida A., Free PMC Article | 04/2/2022 |
| Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. | Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
García-Alfonso P, Saiz-Rodríguez M, Mondéjar R, Salazar J, Páez D, Borobia AM, Safont MJ, García-García I, Colomer R, García-González X, Herrero MJ, López-Fernández LA, Abad-Santos F., Free PMC Article | 03/19/2022 |
| Dihydropyrimidine dehydrogenase (DPYD) gene c.1627A>G A/G and G/G genotypes are risk factors for lymph node metastasis and distant metastasis of colorectal cancer. | Dihydropyrimidine dehydrogenase (DPYD) gene c.1627A>G A/G and G/G genotypes are risk factors for lymph node metastasis and distant metastasis of colorectal cancer.
Zeng J, Wu H, Huang Q, Li J, Yu Z, Zhong Z., Free PMC Article | 02/26/2022 |
| Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy. | Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
Shakeel F, Fang F, Kwon JW, Koo K, Pasternak AL, Henry NL, Sahai V, Kidwell KM, Hertz DL. | 12/4/2021 |